Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
This study was registered at www.clinicaltrials.gov as #NCT02519452.
Conclusions: the frequencies of infections in maternal-fetal health were considered low, highlighting on syphilis and the presence for sickle cell trait.Resumo Objetivos: estimar a taxa de detec ção de patologias da TPN em papel de filtro nas regiões Sul e Sudoeste do Estado da Bahia, bem como delinear o perfil epidemiológico dessas gestantes, calcular e estimar a taxa de adesão e abrangência de cobertura do Programa. Métodos: estudo descritivo, de agosto 2013 a agosto de 2015, de d ados obtidos do Labimuno/ICS/UFBA. Resultados: foram incluídas 64.743 gestantes; as m&e...
Conditions: Advanced Solid Tumors; B Cell Lymphoma; Multiple Myeloma Intervention: Drug: DeltaRex-G Sponsor: Aveni Foundation Temporarily not available
Condition: Multiple Myeloma Interventions: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone Sponsor: GlaxoSmithKline Not yet recruiting
Conditions: Advanced Malignant Solid Neoplasm; Caregiver; Metastatic Malignant Solid Neoplasm; Recurrent Leukemia; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Plasma Cell Myeloma Intervention: Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Bone Marrow Transplantation, Published online: 16 September 2019; doi:10.1038/s41409-019-0671-5Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up
Bone Marrow Transplantation, Published online: 16 September 2019; doi:10.1038/s41409-019-0681-3Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant
AbstractLusutrombopag (Mulpleta®), an orally bioavailable, small molecule thrombopoietin receptor agonist, is approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. In placebo-controlled phase 3 clinical trials, lusutrombopag significantly increased the proportion of patients who did not require a platelet transfusion prior to the procedure or rescue therapy for bleeding up to 7 days after the scheduled procedure. Lusutrombopag also significantly increased the proportion of patients wh o were responders (i.e. had a platelet count&...
This study was carried out at a tertiary care hospital in Haryana. The prevalence of anemia in females at the time pregnancy diagnosis during first trimester was studied. The study period was January 2018 to June 2019. Severity of anemia was categorized as mild (hemoglobin 10 –10.9 gm/dl), moderate (hemoglobin 7–9.9 gm/dl) and severe (hemoglobin
ConclusionActual body weight and bone marrow involvement may be utilized as potential predictive indicators of R-IRRs. Further study is needed to validate these indicators and determine appropriate utilization in practice.
Conclusion: Based on these results NDDS is considered to be an applicable instrument for identifying personality pathology in patients with depressive symptoms, by recognizing the specific pattern. This is thought to be important for adequate treatment planning. PMID: 31517547 [PubMed - as supplied by publisher]